PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Clinical trial NCT04506281 · UNKNOWN
Trial details
- NCT number
- NCT04506281
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-10
- Primary completion
- 2021-08-01
- Enrollment
- 128
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.